Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
1998-12-24
|
pubmed:abstractText |
Tissue levels of the endogenous excitatory amino acid receptor antagonist kynurenic acid (KYNA) and of its bioprecursor L-kynurenine were measured in rats of different ages after d-amphetamine administration. In adult animals, extracellular KYNA concentrations were also determined in vivo by hippocampal microdialysis. In the adult brain, d-amphetamine caused a transient, dose-dependent decrease in tissue content and extracellular levels of KYNA, reaching a nadir of approximately 70% of control values after 1 h at 5 mg/kg. Quantitatively similar decrements were observed in four different brain regions. Seven, 14 and 28-day-old pups were particularly sensitive to the drug, showing a reduction in forebrain KYNA levels to 25%, 40% and 35% of control values, respectively, 1 h after the administration of 5 mg/kg d-amphetamine. Notably, no changes in brain L-kynurenine levels and in liver L-kynurenine and KYNA concentrations were found after d-amphetamine administration. Thus, endogenous monoamines released by d-amphetamine may interfere with the transamination of L-kynurenine to KYNA specifically in the brain. These results suggest that d-amphetamine increases excitatory amino acid receptor function temporarily by reducing the levels of endogenous KYNA.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Central Nervous System Stimulants,
http://linkedlifedata.com/resource/pubmed/chemical/Dextroamphetamine,
http://linkedlifedata.com/resource/pubmed/chemical/Excitatory Amino Acid Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Kynurenic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Kynurenine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0006-8993
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
17
|
pubmed:volume |
802
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
111-8
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:9748528-Animals,
pubmed-meshheading:9748528-Animals, Newborn,
pubmed-meshheading:9748528-Brain,
pubmed-meshheading:9748528-Central Nervous System Stimulants,
pubmed-meshheading:9748528-Dextroamphetamine,
pubmed-meshheading:9748528-Excitatory Amino Acid Antagonists,
pubmed-meshheading:9748528-Extracellular Space,
pubmed-meshheading:9748528-Kynurenic Acid,
pubmed-meshheading:9748528-Kynurenine,
pubmed-meshheading:9748528-Liver,
pubmed-meshheading:9748528-Male,
pubmed-meshheading:9748528-Rats,
pubmed-meshheading:9748528-Rats, Sprague-Dawley,
pubmed-meshheading:9748528-Tissue Distribution
|
pubmed:year |
1998
|
pubmed:articleTitle |
Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain.
|
pubmed:affiliation |
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore 21228, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|